Cargando…

Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy

PURPOSE: The present study aimed to compare immune activation among different irradiated sites and identify potential short-term efficacy prognostic factors in patients with advanced squamous cell esophageal carcinoma (ESCC) who received radiotherapy (RT) and immunotherapy. PATIENTS AND METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengying, Cai, Guoxin, Gao, Zhenhua, Meng, Xue, Han, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206221/
https://www.ncbi.nlm.nih.gov/pubmed/37234974
http://dx.doi.org/10.3389/fonc.2023.1117648
_version_ 1785046180701405184
author Li, Mengying
Cai, Guoxin
Gao, Zhenhua
Meng, Xue
Han, Xiao
author_facet Li, Mengying
Cai, Guoxin
Gao, Zhenhua
Meng, Xue
Han, Xiao
author_sort Li, Mengying
collection PubMed
description PURPOSE: The present study aimed to compare immune activation among different irradiated sites and identify potential short-term efficacy prognostic factors in patients with advanced squamous cell esophageal carcinoma (ESCC) who received radiotherapy (RT) and immunotherapy. PATIENTS AND METHODS: We recorded the clinical characteristics, blood cell counts, and derived blood index ratios, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), at three time points (before, during, and after RT) in 121 patients with advanced ESCC who had received RT and immunotherapy. Chi-square test and univariate and multivariate logistic regression analyses were used to calculate the relationships among inflammatory biomarkers (IBs), irradiated sites, and short-term efficacy. RESULTS: Delta-IBs were calculated as (medio-IBs - pre-IBs) ÷ pre-IBs. The medians of delta-LMR, and delta-ALC were the highest, whereas the median of delta-SII was the lowest in patients with brain radiation. Treatment responses were observed within 3 months after RT or until the beginning of the next line therapy, and the disease control rate (DCR) was 75.2%. The areas under the receiver operating characteristic curve (AUCs) for delta-NLR and delta-SII were 0.723 (p = 0.001) and 0.725 (p < 0.001), respectively. Multivariate logistic regression analysis showed that the treatment lines of immunotherapy (odds ratio [OR], 4.852; 95% confidence interval [CI], 1.595-14.759; p = 0.005) and delta-SII (OR, 5.252; 95% CI, 1.048-26.320; p = 0.044) were independent indicators of short-term efficacy. CONCLUSION: In this study, we found that RT to the brain had a stronger immune activation effect than RT to extracranial organs. We also found that earlier-line immunotherapy plus RT and a decrease in SII during RT may generate better short-term efficacy in advanced ESCC.
format Online
Article
Text
id pubmed-10206221
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102062212023-05-25 Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy Li, Mengying Cai, Guoxin Gao, Zhenhua Meng, Xue Han, Xiao Front Oncol Oncology PURPOSE: The present study aimed to compare immune activation among different irradiated sites and identify potential short-term efficacy prognostic factors in patients with advanced squamous cell esophageal carcinoma (ESCC) who received radiotherapy (RT) and immunotherapy. PATIENTS AND METHODS: We recorded the clinical characteristics, blood cell counts, and derived blood index ratios, including neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII), at three time points (before, during, and after RT) in 121 patients with advanced ESCC who had received RT and immunotherapy. Chi-square test and univariate and multivariate logistic regression analyses were used to calculate the relationships among inflammatory biomarkers (IBs), irradiated sites, and short-term efficacy. RESULTS: Delta-IBs were calculated as (medio-IBs - pre-IBs) ÷ pre-IBs. The medians of delta-LMR, and delta-ALC were the highest, whereas the median of delta-SII was the lowest in patients with brain radiation. Treatment responses were observed within 3 months after RT or until the beginning of the next line therapy, and the disease control rate (DCR) was 75.2%. The areas under the receiver operating characteristic curve (AUCs) for delta-NLR and delta-SII were 0.723 (p = 0.001) and 0.725 (p < 0.001), respectively. Multivariate logistic regression analysis showed that the treatment lines of immunotherapy (odds ratio [OR], 4.852; 95% confidence interval [CI], 1.595-14.759; p = 0.005) and delta-SII (OR, 5.252; 95% CI, 1.048-26.320; p = 0.044) were independent indicators of short-term efficacy. CONCLUSION: In this study, we found that RT to the brain had a stronger immune activation effect than RT to extracranial organs. We also found that earlier-line immunotherapy plus RT and a decrease in SII during RT may generate better short-term efficacy in advanced ESCC. Frontiers Media S.A. 2023-05-10 /pmc/articles/PMC10206221/ /pubmed/37234974 http://dx.doi.org/10.3389/fonc.2023.1117648 Text en Copyright © 2023 Li, Cai, Gao, Meng and Han https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Mengying
Cai, Guoxin
Gao, Zhenhua
Meng, Xue
Han, Xiao
Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title_full Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title_fullStr Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title_full_unstemmed Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title_short Inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
title_sort inflammatory biomarkers as predictors of immune activation to different irradiated sites and short-term efficacy in advanced squamous cell esophageal carcinoma received radioimmunotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206221/
https://www.ncbi.nlm.nih.gov/pubmed/37234974
http://dx.doi.org/10.3389/fonc.2023.1117648
work_keys_str_mv AT limengying inflammatorybiomarkersaspredictorsofimmuneactivationtodifferentirradiatedsitesandshorttermefficacyinadvancedsquamouscellesophagealcarcinomareceivedradioimmunotherapy
AT caiguoxin inflammatorybiomarkersaspredictorsofimmuneactivationtodifferentirradiatedsitesandshorttermefficacyinadvancedsquamouscellesophagealcarcinomareceivedradioimmunotherapy
AT gaozhenhua inflammatorybiomarkersaspredictorsofimmuneactivationtodifferentirradiatedsitesandshorttermefficacyinadvancedsquamouscellesophagealcarcinomareceivedradioimmunotherapy
AT mengxue inflammatorybiomarkersaspredictorsofimmuneactivationtodifferentirradiatedsitesandshorttermefficacyinadvancedsquamouscellesophagealcarcinomareceivedradioimmunotherapy
AT hanxiao inflammatorybiomarkersaspredictorsofimmuneactivationtodifferentirradiatedsitesandshorttermefficacyinadvancedsquamouscellesophagealcarcinomareceivedradioimmunotherapy